Gujarat Themis Biosyn Limited reported its financial results for the quarter and fiscal year ended March 31, 2026. The company concluded the fiscal year with robust volume growth and operational efficiencies, leading to margin expansion. For Q4 FY26, revenue from operations increased 17.22% year-on-year to Rs 44.23 crore. EBITDA for the quarter rose 20.71% to Rs 19.36 crore, with an EBITDA margin of 43.79%. Profit After Tax (PAT) stood at Rs 10.89 crore, and the EPS for the quarter was Rs 1.00.

Quarterly Financial Highlights

The following table summarizes the company's key financial metrics for Q4 FY26 compared to Q4 FY25:

Annual Performance

For the full year FY26, the company reported revenue from operations of Rs 165.82 crore, a growth of 9.96% compared to the previous year. EBITDA for the year was Rs 75.53 crore, while PAT stood at Rs 46.68 crore. The annual EPS was recorded at Rs 4.28. The management attributed the performance to optimized production, higher sales volumes, and cost rationalizations which offset rising manpower costs.

Strategic Expansion Initiatives

The company is pursuing significant inorganic expansion to complement its organic growth. It has signed an asset purchase agreement to acquire a portfolio of 13 brands from Sanofi, France, for approximately EUR 158 million. This asset-light acquisition is expected to be EPS accretive and provide immediate access to regulated markets across 55+ countries. Additionally, the company has signed a share purchase agreement to acquire 100% of MicroBiopharm Japan Co., Ltd. for JPY 21.5 billion (approximately INR 1,300 crores). This transaction, expected to close in Q2 FY2027, will enhance its CDMO capabilities and biotechnology know-how.

Capex and Future Outlook

The company continues to invest in capacity expansion and sustainability. Its R&D and API units are operational, and a new fermentation block development is complete. R&D spend for FY26 was approximately 9% of the topline. Furthermore, the company is establishing a hybrid wind-solar power plant in Gujarat with a capacity of ~18 MW for captive consumption, aimed at reducing power costs and carbon footprint.

Gujarat Themis Biosyn Limited has expanded its global footprint by incorporating a wholly owned subsidiary in Japan. The new entity, named Themis Biosyn Japan Limited, was established on May 19, 2026. This strategic move marks the company's entry into the Japanese market, aligning with its broader business objectives.

Subsidiary Details

The incorporation of Themis Biosyn Japan Limited was completed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The subsidiary is fully owned by Gujarat Themis Biosyn Limited , which holds 100% of its shareholding.

Financial and Operational Information

The newly formed subsidiary has a share capital of Ten Lakhs Yen. As it is a recently incorporated entity, its turnover is currently not applicable. The subsidiary will operate within the pharmaceutical industry, consistent with the parent company's core business sector.

Key Particulars of the Subsidiary

The company has confirmed that no specific governmental or regulatory approvals were required for this incorporation. The business registration extract for the new entity is expected to be received at a later date.